ENDURANCE Pagani DT Flashcards
0
Q
Date end enrollment?
A
Q2 2012
1
Q
Start of study?
A
Q2 2010
2
Q
Primary Endpoint?
A
Survival @2 years free from disabling stroke (MRS >4@24 weeks post-stroke) & alive on original device, transplant or explant for recovery
3
Q
Secondary end points?
A
- Adverse events INTERMACS
- KCCQ & EuroQoL
- NYHA Class & 6-min. Walk Test
4
Q
N=?
A
446
HVAD=297
HMII=148
5
Q
Baseline TR?
A
HVAD 11.8%
HMII 5.4%
6
Q
Overall Primary Endpoint?
A
HMII 57.4%
HVAD 55%
7
Q
Overall Primary Endpoint Sintered?
A
HMII 57.4%
HVAD 57.5%
8
Q
Sintered N=?
Non-Sintered N=?
HMII N=?
A
Sintered N=200
Non-Sintered N=97
HMII N=148
9
Q
Success?
A
HMII= 57.4%
HVAD= 57.5%
10
Q
ADVERSE EVENTS
DIED?
A
HVAD 103 (34.7%)
HMII 39 (26.4%)
11
Q
ADVERSE EVENTS
Malfunction Exchange Urgent Explant?
A
HMII 24 (16.2%)
HVAD 26 (8.8%)
12
Q
ADVERSE EVENTS
Disabling Stroke?
A
HMII 0
HVAD 3 (1.0%)
13
Q
Overall Survival?
A
HMII 67.6%
HVAD 60.2%
14
Q
Overall Survival Sintered?
A
HMII 67.6%
HVAD 61.4%
